Company intelligence / Profile preview

Hudson Therapeutics, Inc.

Durham, North Carolina, United Stateshudsontherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead asset NuGel shows promising results in atopic dermatitis Phase IIb trial

Therapeutic areas: DermatologyNeurologyInfectious Diseases
Modalities: Small molecules/inflammasome inhibitors
Industry: Biotech

Drug pipeline

1 asset

NuGel

Phase 2

Indications: Atopic dermatitis

Partnerships

Actively pursuing partnerships with specialty pharmaceutical companies for licensing/commercialization of NuGel and other assets. Specific partners not yet announced but described as top-tier pharma companies with strong interest.

Beyond the preview

Go deeper on Hudson Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hudson Therapeutics, Inc..

Explore the full profile